Crossmark

Vaccines for established cancer: overcoming the challenges posed by immune evasion

Crossref DOI link: https://doi.org/10.1038/nrc.2016.16

Published Online: 2016-03-11

Published Print: 2016-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

van der Burg, Sjoerd H.

Arens, Ramon

Ossendorp, Ferry

van Hall, Thorbald

Melief, Cornelis J. M.
License Information

Text and Data Mining valid from 2016-03-11
More Information

Article History

First Online: 11 March 2016

Competing interests

: C.J.M.M. reports having a stock-appreciation right that is the equivalent of a stock option in 1% of the issued share capital of ISA Pharmaceuticals, Leiden, Netherlands, is being named as an inventor on the patent for the use of synthetic long peptides as vaccines and is employed as Chief Scientific Officer by ISA Pharmaceuticals, which exploits this patent. S.H.v.d.B. is one of the inventors on the patent for the use of synthetic long peptides as a vaccine but holds no financial interest. S.H.v.d.B. serves as a paid member of the strategy board of ISA Pharmaceuticals. S.H.v.d.B. and T.v.H. are named as inventor on a patent indicating natural killer cell receptor A (NKG2A) as checkpoint molecule involved in vaccine therapy and receive research support from Innate Pharma, Marseille, France, for their studies on this topic. F.O. and C.J.M.M. are named as inventor on a patent involving an improved Toll-like receptor 2 (TLR2) ligand (Amplivant, manufactured by ISA Pharmaceuticals) as an adjuvant for defined T cell vaccines. R.A. declares no competing interests.